We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
NexDx Raises $2.6 million in Series B Financing and Capital Term Loan
News

NexDx Raises $2.6 million in Series B Financing and Capital Term Loan

NexDx Raises $2.6 million in Series B Financing and Capital Term Loan
News

NexDx Raises $2.6 million in Series B Financing and Capital Term Loan

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "NexDx Raises $2.6 million in Series B Financing and Capital Term Loan"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

NexDx, Inc. has announced the successful closing of a $2.1 million Series B financing led by founding investor, City Hill Ventures, LLC, and a $500,000 capital term loan from Silicon Valley Bank.

“This financing by City Hill Ventures, Silicon Valley Bank, and other investors is strong validation of NexDx’s approach to transforming the quality of biomarkers and tests for rheumatologists, patients, and biopharmaceutical companies,” said Jonathan Lim, M.D., NexDx’s Chairman and CEO.

Lim continued, “More importantly, it provides NexDx with sufficient capital to advance the development of our technology platform and tackle the important issue of improving the diagnosis of patients with rheumatoid arthritis, an area of significant unmet medical need.”

“We are excited to partner with NexDx and provide them with the financing they need to develop and grow their solution for rheumatoid arthritis and other autoimmune diseases,” said Mike White, senior relationship manager at Silicon Valley Bank.

White continued, “Silicon Valley Bank is committed to providing life science companies at all stages of growth with the right financial products and services for their specific needs. We look forward to building a longstanding relationship with the NexDx team.”

Advertisement